Barbie-maker Mattel and OpenAI partner to develop AI-powered products
Barbie-maker Mattel is partnering with OpenAI to develop generative AI-powered toys and games, as the new technology disrupts a wide range of industries, Mattel announced Thursday.
Mattel billed the alliance as a "strategic collaboration to support AI-powered products and experiences based on Mattels' brands." It added that the pair would likely announce their first product later this year, as the toymaker strives to get ahead of the AI curve.
The collaboration will combine Mattel's most well-known brands — including Barbie, Hot Wheels, American Girl and more — with OpenAI's generative AI capabilities to develop new types of products and experiences, the companies said.
"By using OpenAI's technology, Mattel will bring the magic of AI to age-appropriate play experiences with an emphasis on innovation, privacy and safety," Mattel said in the statement. It added that any AI woven into toys or games would be used in a safe and secure manner.
On the corporate front, Mattel said it plans to leverage OpenAI's business tools including ChatGPT Enterprise — an enhanced version of ChatGPT designed for businesses — to power new product development.
The collaboration is yet another signal that virtually no field is insulated from disruption by AI. Mattel touts OpenAI's tools as having the ability to improve both its business operations and enhance its product development processes. Initially promoted as a way to automate mundane tasks and free up humans to do more creative jobs, generative AI tools are becoming increasingly sophisticated and capable of doing more than just rote work.
OpenAI Chief Operating Officer Brad Lightcap said the company is "pleased to work with Mattel as it moves to introduce thoughtful AI-powered experiences and products into its iconic brands, while also providing its employees the benefits of ChatGPT."
"With OpenAI, Mattel has access to an advanced set of AI capabilities alongside new tools to enable productivity, creativity and companywide transformation at scale," he added in a statement.
Amid flagging toy sales, Mattel has leveraged its intellectual property to produce other forms of entertainment, including movies, television and mobile games. The company's studio arm has a slate of more than a dozen films planned based on its famous toy brands, following the success of its 2023 "Barbie" movie.
Mattel is also among a number of large U.S. retailers that have pulled their financial guidance amid ongoing economic uncertainty. Last month, Mattel paused its full-year guidance for 2025 citing tariff-driven uncertainty. The company also said it would raise prices on some goods to offset added costs form tariffs.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
Solar can drive jobs, equity, climate goals — but investment still uneven
New Delhi: The Sixth Meeting of the ISA Regional Committee for Europe and the Others Region was held in Brussels with participation from 20 countries and partners to review solar energy progress and advance global collaborations under the International Solar Alliance (ISA). The meeting was chaired by Germany, the regional Vice President, and convened to align strategic priorities and assess implementation status across member nations. ISA Director General Ashish Khanna said, 'Your presence here today reflects our shared commitment to advancing the global transition to solar energy. Our focus must now turn to ensuring these advancements translate into jobs, equity, and climate resilience.' He added that $2 trillion was invested in clean energy last fiscal, with solar photovoltaics leading, but only 15% of it reached low- and middle-income countries and less than 2% was directed to Africa. Highlighting energy access challenges, Khanna said 600 million people in Africa remain without electricity access. 'ISA is mobilising $200 million to leverage more than 30 times the private investment in Distributed Renewable Energy in Africa,' he added. Tobias Rinke, Deputy Head of Division, Federal Ministry for Economic Affairs and Energy, Germany, said the alliance's membership has grown to 123 countries with doubling of active engagements since 2022. He referenced COP28 commitments, where nearly 200 countries agreed to triple renewable capacity and transition from fossil fuels. 'Solar energy plays a central role in achieving these goals,' he said. In a session with ISA Director General, IEA's Laura Cozzi said, 'AI-related infrastructure could add electricity demand equivalent to a 'new Japan' by 2030.' She said AI can optimise grid operations and improve energy access. She also announced the launch of an Energy and AI Observatory by the IEA. In a separate session, CIFF CEO Kate Hampton said the key financing challenge is the shortage of catalytic equity rather than debt. She said philanthropy can fill this gap and support country platforms with technical assistance, policy engagement, and junior equity. 'A major constraint lies in the availability of skilled professionals capable of navigating delivery, policy, and finance,' she added. European Commissioner for Energy and Housing Dan Jørgensen, in his keynote address, said the cost of solar power has dropped 82% in the EU over the past decade. He said an additional 12% global decline in 2023 made solar the fastest-growing and most affordable clean energy source today. Upcoming discussions at the meeting include topics on Catalytic Finance in Africa, ISA's STAR-Cs initiative, AI in the energy sector, and a roundtable on energy storage and green hydrogen .
Globe and Mail
2 days ago
- Globe and Mail
NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies
DelveInsight's, 'Non-Small-Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the NSCLC Treatment Landscape. Click here to read more @ NSCLC Pipeline Outlook Key Takeaways from the NSCLC Pipeline Report In June 2025, Revolution Medicines Inc. announced a study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel. This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy. In June 2025, Amgen conducted a study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR). In June 2025, Allist Pharmaceuticals Inc. organized a Phase 3 clinical study to assess the efficacy and safety of adjuvant treatment with firmonertinib versus placebo in participants with Stage IB-IIIB NSCLC with uncommon EGFR mutations (exon 20 insertions, PACC and classical-like mutations) after complete surgical resection with or without adjuvant chemotherapy. In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC. DelveInsight's NSCLC pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for NSCLC treatment. The leading NSCLC Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Promising NSCLC Pipeline Therapies such as Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. Stay informed about the cutting-edge advancements in NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ NSCLC Clinical Trials Assessment NSCLC Emerging Drugs Profile AMG 510: Amgen AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC. CMP 001: Cytos Biotechnology CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer. The NSCLC Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment. NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different NSCLC mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market Learn more about NSCLC Drugs opportunities in our groundbreaking NSCLC research and development projects @ NSCLC Unmet Needs NSCLC Companies GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Parenteral Intramuscular Molecule Type NSCLC Products have been categorized under various Molecule types such as Small molecules Peptides Polymer Gene Therapy Monoclonal antibodies Product Type Discover the latest advancements in NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ NSCLC Market Drivers and Barriers, and Future Perspectives Scope of the NSCLC Pipeline Report Coverage- Global NSCLC Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. NSCLC Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of NSCLC Pipeline on our website @ NSCLC Emerging Drugs and Companies Table of Contents Introduction Executive Summary Non-Small-Cell Lung cancer (NSCLC): Overview Pipeline Therapeutics Therapeutic Assessment Non-Small-Cell Lung cancer (NSCLC) – DelveInsight's Analytical Perspective In-depth Commercial Assessment Late Stage Products (Pre Registration) AMG 510: Amgen Drug profiles in the detailed report….. Mid Stage Products (Phase II) Drug Name: Company Name Drug profiles in the detailed report….. Early Stage Products (Phase I) CMP 001: Cytos Biotechnology Inactive Products Non-Small-Cell Lung cancer (NSCLC) Key Companies Non-Small-Cell Lung cancer (NSCLC) Key Products Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion Non-Small-Cell Lung cancer (NSCLC) Analyst Views Non-Small-Cell Lung cancer (NSCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Washington Post
2 days ago
- Washington Post
Jean Smart and John Krasinski in solo shows that illustrate the gender wars
NEW YORK — A dramatic faceoff of Judith Butler proportions is underway on New York stages, where a pair of star vehicles is condemning the tyranny of conventional gender roles from each side of the divide. Depending whom you ask, men and women are both in trouble. Several waves of feminism have decried the injustices facing the latter: subjugation under patriarchy with fallouts that range from unequal pay to death. Enter 'Hacks' star Jean Smart in 'Call Me Izzy,' as a hothouse flower whose artistic aspirations are suffocated by her unseen ogre of a husband. Pressure to escape the trailer park is paramount. Meanwhile, rumblings that began on the dark web and are now broadcast on something called the manosphere have reached the opposite conclusion: It's men whose well-being is threatened under the current regime, one that the red-pilled nice guy played by John Krasinski in 'Angry Alan' calls 'the gynocracy.' That would be a world governed in deference to women that ignores men's loneliness and insecurities while demanding they be heroes and moneymakers. (Straight people are a trip.) Arguments anchoring each end of this age-old tug-of-war are everywhere. Throw in the economic appeal of producing celebrity solo shows, and it's no wonder the debate is being hashed out on Midtown stages. Despite their opposing perspectives, they present the actors with identical challenges — proving that vulnerability is the ultimate common ground. The familiarity of domestic violence narratives allows for a naturalistic approach — Izzy, in all her delicacy and emotional candor, would be impossible not to root for. A few minutes with Smart's graceful, fluttering narrator, as she toils and daydreams on the can, and you would practically kill for her. A Louisiana belle who was married by 17, Izzy spills with dishy Southern talk, sweeter than gossip but with the same conspiratorial flavor. Call this corner of her modest digs 'A Bathroom of One's Own.' It's where she hides out to scrawl poetry on toilet paper, using the hamper as a desk and stashing reams of words in a box of Tampax. Dressed in a plush teal bathrobe, her face framed with frizzy golden curls, she recalls reciting Joyce Kilmer's 'Trees' in a childhood pageant and falling in love with 'mind pictures,' a phrase she borrows from Zora Neale Hurston. Of course, Izzy's husband wouldn't approve of her literary pursuits, and this being a drama, he's bound to find out. The world premiere from playwright Jamie Wax, who's also a correspondent for CBS News, treads sensitive but familiar territory. The plight of a woman's authorship curtailed has been covered with much greater sophistication elsewhere — including in previous centuries, by women writers themselves. The appeal of this borderline Southern Gothic production, from director Sarna Lapine, lies entirely with its beguiling star. Smart, returning to Broadway after some 25 years, brings astonishing clarity and depth to the part. Spinning an enticing yarn from shopworn material — the action is set in 1989, when it may have struck a modern tone — she delivers a performance that feels deceptively featherlight while demonstrating total command. She lends Izzy's tin-eared poetry a soaring lyricism and Wax's trope-heavy script the texture of a character study. Every expression feels alive, and the sum total is transfixing. 'Angry Alan,' the first show at the newly christened Studio Seaview off-Broadway, takes a different tack. Written by Penelope Skinner and created with Donald Sage Mackay, the show is premised on the fact that engendering compassion for a man in need is a trickier prospect. Especially when that man has plunged down a slippery wormhole into an online realm led by a man-fluencer named Angry Alan. Here, male grievances — many of them legitimate — assume a sour cast by turning the blame on women. It's true that men are in crisis. Among the dilemmas cited by Roger, a cheery everyman not unlike Krasinski's character on 'The Office,' are elevated rates of suicide and 'a period of unprecedented uncertainty' that's confused men about their place in the culture and at home. Given that men are not, as the stereotype goes, particularly forthcoming with expressing emotion, the gag is that Roger has the audience as his unlikely confessor. Skinner and Mackay, who premiered the show at the 2018 Edinburgh Festival Fringe in Scotland, set out an uneasy game in which Roger flips, repeatedly and on a dime, from relatable to revolting. Roger is an avatar, a stand-in for 'you know the type,' in this exploration of a sociological problem, directed with shadowy, uncanny undertones by Sam Gold. (The setup is not unlike Young Jean Lee's 'Straight White Men,' which played Broadway in 2018.) Roger has particulars — an ex-wife, who glowers down from the conference-like projections, a big-shot job that ended badly at AT&T (he now works at Kroger) and a new girlfriend who's recently (and conveniently, plot-wise) undergone a feminist awakening. Even as he buys into Alan's dark talk, Roger is posited as a generic good-natured dude trying to get by. So it goes that by design, Krasinski mostly plays mild-mannered, which fans know he's ideally suited for. Though they won't be disappointed here, Krasinski is better when he gets more to do, such as voicing Roger in conversation with his girlfriend, who's bewildered by his slide into men's rights. In the end, Roger's fixation on the double binds of masculinity faces a provocative test (which I won't spoil here) that snaps the whole play into focus. It's an affecting shift, but the stakes might have been clarified sooner. At the heart of 'Angry Alan' is the tension between how Roger really feels — the suffering he admits he's long buried inside — and the sturdy exterior he's been conditioned to wear as a mask. The difference in consequence between the two stories comes down to that adage about men, like Alan, being afraid that women will laugh at them. Women like Izzy, on the other hand, put on a pleasant face to avoid a far worse fate. Call Me Izzy, through Aug. 17 at Studio 54 in New York. 90 minutes without an intermission. Angry Alan, through Aug. 3 at Studio Seaview in New York. 85 minutes without an intermission.
